Literature DB >> 12383573

Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care.

Soccorso Capomolla1, Oreste Febo, Monica Ceresa, Angelo Caporotondi, Giampaolo Guazzotti, Maria La Rovere, Marina Ferrari, Francesca Lenta, Sonia Baldin, Chiara Vaccarini, Marco Gnemmi, GianDomenico Pinna, Roberto Maestri, Paola Abelli, Sandro Verdirosi, Franco Cobelli.   

Abstract

OBJECTIVE: This study compared the effectiveness and cost/utility ratio between a heart failure (HF) management program delivered by day-hospital (DH) and usual care in chronic heart failure (CHF) outpatients.
BACKGROUND: Previous studies showed that about 50% of readmissions for CHF can be prevented by a multidisciplinary approach. However, the performance, effectiveness, and cost/utility ratio of a process of HF outpatient management related to evidence-based medicine have not been considered.
METHODS: A total of 234 prospective patients discharged by a HF Unit were randomized to two management strategies: 122 patients to usual community care and 112 patients to a HF management program delivered by the DH. Management (rate of readmissions, therapeutic interventions), functional parameters (New York Heart Association [NYHA] functional class, left ventricular diameters, and ejection fraction, deceleration time of early diastolic mitral flow, peak oxygen uptake, and mitral regurgitation) and hard outcomes (cardiac death and urgent cardiac transplantation) were evaluated. The cost/utility ratios of the two strategies were compared.
RESULTS: After 12 +/- 3 months of follow-up, the individual rate access in DH was 5.5 +/- 3.8 days. The DH subjects were readmitted to the hospital less frequently than were the usual-care group patients (13 vs. 78, p < 0.00001). Patients allocated to usual-care management showed heterogeneous changes in NYHA functional class (13% improved and 16% worsened p = NS); In contrast, the DH group showed significant changes in NYHA functional class (23% improved and 11% worsened, p < 0.009). Hard cardiac events in the one-year follow-up occurred in 25/234 (10.6%) patients; cardiac death occurred in 21/122 (17.2%) of the community group and in 3/112 (2.7%) in the DH group (p < 0.0007). One DH patient underwent urgent transplantation. Comparison of the two managerial models by Cox regression analysis showed that DH management significantly protected against the appearance of hard events (relative risk [RR] 0.17; confidence interval [CI] 0.06 to 0.66). The cost/utility ratio of the two management strategies was similar (usual care $2,409 vs. DH $2,244). The incremental analysis revealed a cost savings of $1,068 for each quality-adjusted life year gained. The cost/utility ratio for the integration of DH management of CHF was $19,462 (CI $13,904 to $34,048).
CONCLUSIONS: A heart failure outpatient management program delivered by a DH can reduce mortality and morbidity of CHF patients. This management strategy is cost-effective and has an equitable value from a societal point of view.

Entities:  

Mesh:

Year:  2002        PMID: 12383573     DOI: 10.1016/s0735-1097(02)02140-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  37 in total

Review 1.  The effectiveness of chronic care management for heart failure: meta-regression analyses to explain the heterogeneity in outcomes.

Authors:  Hanneke W Drewes; Lotte M G Steuten; Lidwien C Lemmens; Caroline A Baan; Hendriek C Boshuizen; Arianne M J Elissen; Karin M M Lemmens; Jolanda A C Meeuwissen; Hubertus J M Vrijhoef
Journal:  Health Serv Res       Date:  2012-03-14       Impact factor: 3.402

2.  Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial.

Authors:  Anique Ducharme; Odette Doyon; Michel White; Jean L Rouleau; James M Brophy
Journal:  CMAJ       Date:  2005-07-05       Impact factor: 8.262

3.  Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study.

Authors:  Pieta W F Bruggink-André de la Porte; Dirk J A Lok; Dirk J van Veldhuisen; Jan van Wijngaarden; Jan H Cornel; Nicolaas P A Zuithoff; Erik Badings; Arno W Hoes
Journal:  Heart       Date:  2006-10-25       Impact factor: 5.994

4.  Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study.

Authors:  Anja Neumann; Sarah Mostardt; Janine Biermann; Götz Gelbrich; Alexander Goehler; Benjamin P Geisler; Uwe Siebert; Stefan Störk; Georg Ertl; Christiane E Angerrmann; Jürgen Wasem
Journal:  Clin Res Cardiol       Date:  2014-11-18       Impact factor: 5.460

Review 5.  Systematic review of multidisciplinary interventions in heart failure.

Authors:  R Holland; J Battersby; I Harvey; E Lenaghan; J Smith; L Hay
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

Review 6.  Medical day hospital care for older people versus alternative forms of care.

Authors:  Lesley Brown; Anne Forster; John Young; Tom Crocker; Alex Benham; Peter Langhorne
Journal:  Cochrane Database Syst Rev       Date:  2015-06-23

7.  Randomised trial of telephone intervention in chronic heart failure: DIAL trial.

Authors: 
Journal:  BMJ       Date:  2005-08-20

8.  The importance of organizational characteristics for improving outcomes in patients with chronic disease: a systematic review of congestive heart failure.

Authors:  Luci K Leykum; Michael Parchman; Jacqueline Pugh; Valerie Lawrence; Polly H Noël; Reuben R McDaniel
Journal:  Implement Sci       Date:  2010-08-25       Impact factor: 7.327

9.  Community-based care for the specialized management of heart failure: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-11-01

10.  Cost-effectiveness of an intervention to reduce emergency re-admissions to hospital among older patients.

Authors:  Nicholas Graves; Mary Courtney; Helen Edwards; Anne Chang; Anthony Parker; Kathleen Finlayson
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.